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Abstract: For tissue engineering, several cell types and
tissues have been proposed as starting material. Allogenic
skin products available for therapeutic usage are mostly
developed with cell culture and with foreskin tissue of
young individuals. Fetal skin cells offer a valuable solution
for effective and safe tissue engineering for wounds due
to their rapid growth and simple cell culture. By selecting
families of genes that have been reported to be impli-
cated in wound repair and particularly for scarless fetal
wound healing including transforming growth factor-beta
(TGF-b) superfamily, extracellular matrix, and nerve/
angiogenesis growth factors, we have analyzed differences
in their expression between fetal skin and foreskin cells,
and the same passages. Of the five TGF-b superfamily
genes analyzed by real-time reverse transcription–
polymerase chain reaction, three were found to be signifi-
cantly different with sixfold up-regulated for TGF-b2,
and 3.8-fold for BMP-6 in fetal cells, whereas GDF-10
was 11.8-fold down-regulated. For nerve growth factors,
midkine was 36-fold down-regulated in fetal cells, and
pleiotrophin was 4.76-fold up-regulated. We propose that
fetal cells present technical and therapeutic advantages
compared to foreskin cells for effective cell-based therapy
for wound management, and overall differences in gene
expression could contribute to the degree of efficiency
seen in clinical use with these cells. Key Words: Cell
banking—Cell culture—Fetal skin cells—Collagen
scaffolds—Skin tissue engineering—TGF-b.
One of the major challenges of assuring increas-
ing patients benefiting from tissue engineering in
the future is the optimization of the choice of cell
type and their isolation and proliferation. Equally
important is the delivery system of chosen cells and
their interaction with scaffolds to create a three-
dimensional tissue. Although increasing models for
all types of tissues have been proposed which are
related to the increased availability of cell sources
and new biomaterials, it is in the field of cutaneous
replacement that clinical applications have rapidly
advanced for different skin cell/tissue origins.
Several cell types and tissues have been proposed as
starting material for elaborate tissue engineering
processing including autologous skin cells, adult
stem cells, bone marrow, embryonic stem cells,
cadaver skin, acellular dermis, de-epidermized
dermis, allogenous full-thickness skin substitutes,
xenografts, placenta, and amniotic fluid (1–6)
(Table 1A). Their clinical uses have extended signifi-
cantly for a wide variety of indications including
burns, acute and chronic wounds, skin loss, surgical
wounds, and bullous diseases (7). Technically, cell-
based therapies should be relatively simple with
respect to tissue collection, cell culture, cell expan-
sion, and storage. Allogeneic-based therapies would
provide a major advantage for availability when
necessary. Therapeutically, cell-based therapies
should have high wound-healing potential, no
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TABLE 1. Biological products and their composition
A. Autologous products
Product Cell types Advantages Disadvantages
Epicel
Genzyme Biosurgery, Cambridge, MA, USA
Keratinocytes Small and large surfaces Patient biopsy necessary
Several weeks delay
Complicated cell culture
Blistering during heating
Fragile
Laserskin
Fidia Advanced Blopolymers. Padua, Italy
AcuDress
DFB Pharmaceulicals, Fort Worth, TX, USA
Bioseed
BioTissue Technologies, Freiburg, Germany
Autoderm
XCELLentis, Gent, Belgium
MySkin
CellTran, Ltd., Sheffield, UK
Epibase
Genévrier Lab., Sophia-Antipolis, Nice, France
Epidex
Euroderm, Leipzig, Germany
Hair follicle
Keratocytes
Several weeks delay
Complicated cell culture
HC Implants
Leiden, Netherlands
Fibroblasts
Patient biopsy necessary
Several weeks delay
Hyalograft 3D
Fidia Advanced Biopolymers
Autologous Grafting
Karocell Tissue Engineering
Stockholm, Sweden
Keratinocytes/fibroblasts
Patient biopsy necessary
Several weeks delay
Complicated cell culture
Karoskin
Karocell Tissue Engineering
Accelular cadaver dermis for carrier Donor screening difficulties
B. Allogenous products
Product Cell types Advantages Disadvantages
Cadaver skin
Nonprofit skin banks
Intact skin either: cryopreserved,
lyophilized, glycerolized
Immediately available
Small and large surface
Only for cover
Secondary grafting necessary
Donor screening difficulties
Multiple donors
Alloderm
LifeCell,Woodlands, TX, USA
Acellular cadaver dermis
Karoskin
Karoderm
Karocell Tissue Engineering
Cadaver skin
Acellular cadaver dermis
EZDerm
Brennen Medical, St. Paul, MN, USA
Porcine xenograft
Oasis
Healthpoint Ltd., Fort Worth, TX, USA
Porcine xenograft
Small intestine mucosa
Dermagraft
Smith and Nephew, London, UK
Foreskin fibroblasts Multiple donors
Only for cover
Secondary grafting necessary
Trancyte
Smith and Nephew
Foreskin fibroblasts
TransDerm
XCELLentis, Gent, Belgium
Donor keratinocytes
Apligraft
Organogenesis, Canton, MA, USA
Foreskin fibroblasts
Foreskin keratinocytes Immediately available
Small surfaces
Multiple donors
Complicated cell culture
Secondary grafting usually
necessary
OrCellÆ
Ortec Int., New York, NY, USA
Foreskin fibroblasts
Foreskin keratinocytes
Lyphoderm
XCELLentis, Gent, Belgium
Neonatal keratinocytes
Lyophilized
Immediately available
Longer shelf life
Cryoceal
XCELLentis, Gent, Belgium
Donor keratinocytes
Cryopreserved
Allox
DFB Pharmaceuticals, Fort Worth, TX, USA
Foreskin fibroblasts
Foreskin keratinocytes
Spray
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immunological-induced reactions, and no pro-
inflammatory properties.
Until now, the majority of allogenous skin prod-
ucts that have been developed with cell culture are
with donor foreskin tissue cells. The dermal fibro-
blasts and keratinocytes from foreskin cells have
been used in products such as Dermagraft, Tran-
sCyte, and Apligraft, and all clinical data show that
these products alone are not capable of full wound
closure, but are used for wound cover while waiting
for split or mesh grafting (Table 1B) (1,7–9). When
fetal skin fibroblasts are used alone in similar deliv-
ery systems (native collagen), we have shown that
no other surgical means or grafting techniques are
necessary for burns, and acute and chronic wounds
(10,11). Therefore, the limitations of actual prac-
tice may be more in relation to the lower wound-
healing capacities of chosen cell types, which have
been for the most part foreskin fibroblasts and
keratinocytes.
Fetal skin cells, more specifically fetal dermal
fibroblasts, offer an ideal solution for effective and
safe tissue engineering for wounds of all nature for
several reasons including: (i) cell expansion capacity
from one organ donation; (ii) minimal cell growth
requirements; (iii) adaptation to biomaterials for
delivery; and (iv) wound-healing capacity (Fig. 1).
First, fetal skin dermal fibroblasts have extensive
expansion possibilities as it requires only one organ
donation (1–4 cm2 tissue) to create enough frozen
cells to produce a bank capable of making over
270 million fetal skin constructs (9 ¥ 12 cm). Second,
cell culture requirements are minimal compared to
stem or mesenchymal cell types. As the fetal skin
dermal fibroblasts are already differentiated and do
not need to be directed or altered, the vast number
of additional growth factors normally necessary are
not needed for cell culture and expansion. Third,
fetal cells, unlike neonatal, young, or adult cells,
adapt particularly well to biomaterials, allowing effi-
cient and simple delivery to the patient. In our labo-
ratory and in others, it has been shown that cells
from donors (neonatal to adult) are not capable of
efficient integration into various biomaterials, such
as chitosan, and would not support cell attachment
and cell growth resulting in toxicity to cells (12). Ng
et al. (12) have emphasized that physical character-
istics of scaffolds such as porosity and mechanical
stability are important for withstanding cell contrac-
tion forces and assuring a homogenous distribution
of cells throughout the scaffold. We have seen that
fetal cells adapt well to various biomaterials (10).
For processing of a final product for clinical
delivery, both the homologous distribution and the
FIG. 1. Simple, rapid, and secure
bioengineered fetal skin for clinical use.
With one organ donation of 1–4 cm2 of
skin, it is possible to establish a fetal skin
cell bank (Master Cell Bank, MCB or
~2400 vials) which can produce “ready-to-
use” frozen aliquots of cells (Working Cell
Bank vials that are thoroughly screened)
that are evenly pipetted onto collagen
matrix. Only 48 h is necessary to prepare
fetal skin constructs when using cells from
the frozen bank due to their rapid integra-
tion into the collagen matrix, and no
staples, glue, or sutures are necessary for
patient treatment.
Simple Preparation and Application
Thawing (Cells from WCB)
Cellular integration
Patient Application 
Patient need
48
Hours
No staples, glue or 
sutures necessary
Quality control simplified
Cryopreserved cell bank
–165°C (~2,400 Vials, MCB)
Construct Engineering
Flexible biological construct
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rapidity of development of the final product are
major significant advantages. When long culture
periods are necessary as for autologous grafting or
for the commercially available skin products, to date
there is a nonnegligible increased risk for contami-
nation. It is also important to have a process that is
consistent and easily repeated. By developing con-
sistent cell banks with fetal dermal fibroblasts, many
of the risk factors can be eliminated for bringing
safe and effective human cell-based therapies to the
bedside.
Most importantly, the wound-healing capacity
seen with simplified cultured fetal skin dermal
fibroblasts was of excellent quality for deep second-
and third-degree burns, with little hypertrophy,
no retraction, or inflammation of new skin (10).
Overall, many difficulties of tissue engineering such
as immunologic rejection, low growth capacity, and
matrix compatibility could be reduced with fetal
cells.
Differences in gene families, known to have an
impact in the complex process of wound healing,
between fetal skin cells and other cell types already
therapeutically used in humans for several years
could be of importance. Molecular analysis of
wound healing has largely been devoted to cytok-
ines, and most particularly those of the transforming
growth factor (TGF) family and their role in
manipulating cutaneous wound healing and scar for-
mation (13). It has been suggested that scarless
wound healing in fetal skin at early gestation is a
result of the unique cytokine or growth factor
profile (14,15). Of these, TGF-beta (TGF-b) has
been most widely studied as it is implicated in the
transition between scarless healing and repair with
scar formation (16).
We wished to look at possible differences in genes
of the TGF-b superfamily, and those genes involved
in nerve/angiogenesis and extracellular matrix for-
mation, known to have a major impact in wound
healing, between foreskin tissue fibroblasts, that are
widely used for biological skin products, and fetal
skin dermal fibroblasts. These two cell types are pos-
sible for comparison with the same technical specifi-
cations (media requirements and culture time) as
their large upscaling (cell banks) processing is accom-
plished in the same manner. As fetal skin dermal
fibroblasts, at the age and passages used in bioengi-
neered skin, have been shown to be efficient in total
skin repair for burns and wounds, we wished to look
at possible unique cellular and molecular character-
istics of fetal fibroblasts which could contribute to the
overall observed skin repair seen in clinical studies to
date.
MATERIALS AND METHODS
Skin biopsies and cell culture
Cell lines established in the University Depart-
ment of Obstetrics in Lausanne from fetal skin were
used in these studies. Fetal skin biopsies (fetal 1–3, 14
weeks of gestation; fetal 4 and 5, 16 weeks of gesta-
tion) were obtained after pregnancy termination
with informed consent and approval from the local
Medical School Ethics Committee (fetal skin is con-
sidered to be an organ donation under Swiss law up
to this phase of gestation). Neonatal foreskin tissue
was obtained in the Department of Pediatric Surgery
in Lausanne University Hospital.
Skinbiopsiesweredissected into three independent
sections and then into <0.5 mm3 fragments and grown
in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (FBS, Hyclone, Logan, UT,
USA) and glutamine (Sigma, St. Louis, MO, USA).
Cell outgrowth was allowed to 70% confluency, and
cells were frozen in liquid nitrogen for long-term
storage (15–20 units). Cells were used for experimen-
tation between passages 2 and 6, and were grown at
37°C in a humidified atmosphere of 95% air/5%CO2.
Consistent cell banks were established for one of
each tissues (fetal 1 and foreskin) on a large scale for
comparison. From one original 1–4 cm2 biopsy, 100
6 cm plates were seeded with whole tissue fragments
~4 per plate (<0.5 mm3).These fragments were grown
without any external growth factors.When cell growth
advanced after approximately 1 week for fetal tissue,
and 2–3 weeks for foreskin tissue, dishes of tissue and
cells were trypsinized (0.25% trypsin–0.1% ethylene-
diaminetetraacetic acid).At this point, 90 plates were
frozen into individual units in liquid nitrogen. Cells
were centrifuged at 2000 ¥ g for 15 min, and resus-
pended in a freezing solution of DMEM (5 mL) +
FBS (4 mL) + DMSO (1 mL, Fluka, St. Louis, MO,
USA) and frozen in 1 mL aliquots (1 ¥ 107 cells) at
-80°C in Nalgene Cryo 1°C Freezing Containers
(Nalgene, Hereford, UK) to achieve a -1°C/min rate
of cooling and freezing curve. After 24 h, cells were
transferred to liquid nitrogen for longer storage. Ten
plates were amplified to 200 plates for fetal cells (1:20
dilution) and 100 plates for foreskin (1:10 dilution);
190 units were for the secondary frozen stock. These
stocks can be subsequently amplified to create a cell
bank destined for tissue-engineered skin constructs.
RNA extraction and real-time reverse
transcription–polymerase chain reaction (RT–PCR)
Total RNA was isolated from cultured fetal and
foreskin cells at passage 3 using the NucleoSpin,
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RNA II kit (Macherey-Nagel, Düren, Germany) as
described by the manufacturer. The concentration
and purity of each sample were assessed by ab-
sorbance at 260 nm and by the 260/280 nm ratio,
respectively.
One microgram of total RNA was reverse tran-
scribed using the 50 units of StratScript reverse tran-
scriptase enzyme (Stratagene, San Diego, CA, USA)
in a volume of 50 mL containing 1¥ first-strand buffer
(Stratagene), 3 mL of random primers (100 ng/mL)
(Promega, Madison, WI, USA), 40 units of
RNasin (Promega), and 2 mL of dNTP mix 100 mM
(Promega) as described by the manufacturer. The
thermocycler Biometra T-1 (Biometra Biomediz-
inische Analytik GmbH, Göttingen, Germany) was
programmed as follows: 25°C, 10 min; 37°C, 60 min;
and 90°C, 5 min.
Real-time RT–PCR using 160 ng of cDNA was
performed withABI Prism 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA,USA).
We measured the gene expression using already-
designed primers and probes by TaqMan Gene
Expression Assays (Applied Biosystems) of midkine
(MDK or neurite growth-promoting factor 2
[NEGF2]), pleiotrophin (PTN or heparin-binding
growth factor 8, NEGF1),TGF-b1,TGF-b2,TGF-b3,
growth differentiation factor 10 (GDF-10 or
BMP3B), laminin b-1 (LAMb1), dermatopontin
(DPT), bone morphogenic protein 6 (BMP6), and
b-actin (Table 2).
PCR reactions were performed in 25 mL: 11.25 mL
of cDNA sample, 12.5 TaqMan Universal Master Mix
(Applied Biosystems), and 1.25 of already-designed
primers and probes by TaqMan Gene Expression
Assays. Thermal cycle conditions were 50°C, 2 min;
95°C, 10 min, then 50 cycles at 95°C, 15 s; 60°C, 1 min.
Relative gene expression was analyzed with the 2–DDCT
method and normalized to b-actin gene. Measure-
ments were performed in triplicates and reported as
fold difference normalized with the fetal cells and
associated standard deviation of the mean.Data were
analyzed with a one-sided t-test, and differences were
considered significant when P < 0.05.
RESULTS
Cell banking of fetal skin and foreskin tissue cells
Cell banks were prepared from one fetal skin tissue
and one foreskin tissue using the same process but
with some minor differences. The fetal cells could be
easily passaged with a dilution at 1:20 to 1:30,whereas
the foreskin cells remained with the same growth
characteristics when the dilution was 1:10.During the
same time frame, this had an impact on the number of
vials that could be frozen in the final cell bank for the
two tissues. Fetal cell banks could easily be double to
triple of that for the foreskin cell banks.
Real-time RT–PCR expression for TGF-b
superfamily, nerve/angiogenesis factor, and ECM
genes: Differences between fetal skin and foreskin
tissue cells
Out of the five TGF-b superfamily genes tested,
three were differently expressed between fetal skin
and foreskin tissue cells (Fig. 2A). Expression was
considered significant when more than a twofold dif-
ference was seen from the normalized value of the
RT–PCR.There were no differences seen forTGF-b1
(P = 0.063) and TGF-b3 (P = 0.734). For TGF-b2,
there was a 6.05 (P = 0.000003) fourfold difference
with foreskin tissue cells having lower expression. In
the BMPs, BMP6 was seen to have almost 3.8 (P =
0.001) times less expression in foreskin tissue, and
GDF-10 (BMP3B) was almost 11.8 (P = 0.0008)
times less expressed in fetal skin cells (Fig. 2B,C).
For nerve/angiogenesis factors, PTN was 4.76 (P =
0.00000008) more pronounced in fetal skin cells, but
MDK was about 36.4 (P = 0.01) times less expressed
in fetal tissue cells (Fig. 2D,E). Neither of the two
ECM genes (DPT or LAMb1) was seen to be signifi-
cantly higher in fetal skin cells than foreskin tissue
(Fig. 2F,G).
Real-time RT–PCR expression for TGF-b1, -b2,
and -b3 isoform genes and ratios in fetal skin at 14
and 16 weeks gestation
Relative gene expression for the isoforms of
TGF-b was measured in five different fetal tissues
available covering different gestational ages to look
at TGF-b isoform ratios. Relative gene expression is
based on the number of cycles for real-time RT–PCR
to show relative gene expression differences between
the three TGF-b isoforms. No significant difference
was seen for gene expression for five different donors
with gestational age of 14 or 16 weeks (P = 0.233
for TGF-b1, P = 0.210 for TGF-b2, and P = 0.982 for
TGF-b3). There was much more TGF-b1 gene
expression seen in fetal skin than for either of
TGF-b2 andTGF-b3.The ratio of TGF-b1 toTGF-b3
is 21.47 ! 1.98, whereas TGF-b1 to TGF-b2 is
7.24! 0.92 (Fig. 3).
DISCUSSION
We have described herein that there are significant
differences in the cell types that are used for biologi-
cal skin substitutes. We have expanded cells from
both fetal and foreskin tissue into large cell banks
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FIG. 2. Real-time PCR results for TGF-b superfamily, ECM, and nerve/angiogenic genes for fetal skin and foreskin tissue cells from
expanded cell banks. Gene expression was normalized to actin and expressed as a relative value of fetal skin for (A) TGF-b1, b2, b3;
(B) BMP-6; (C) GDF-10; (D) PTN; (E) MDK; (F) DPT; and (G) LAMb1. Expression was significant when a twofold difference was seen from
the normalized value. Measurements were performed in triplicate.
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under the same culture conditions for comparison at
the same passage numbers. Genes involved in wound
healing and those particularly described in fetal
wound healing show major differences of expression
between fetal and foreskin cells. Three highly
homologous TGF-b isoforms are known in humans:
b1, b2, and b3 (13). Each form has been found by
immunohistochemistry in unwounded fetal skin.
However, low levels of TGF-b1 and high levels of
TGF-b3 are expressed at gestational ages associated
with scarless repair (14,15).
Exogenous application of TGF-b1 to normally
scarless fetal wounds resulted in scar formation with
an adultlike inflammatory response observed (16).
The pro-fibrotic nature of TGF-b1, and possibly
TGF-b2, was confirmed in wounds of adult rats
because neutralizing TGF-b1 and b2 with antibodies
partially reduced the amount of scarring (17). How-
ever, antifibrotic properties can be seen with the
isoform TGF-b3 as injection or application of this
isoform showed reduced scarring and inflammation
in adult wounds (17,18). When using a rabbit hyper-
trophic scar model, TGF-b3 was confirmed to show
increased properties in wound healing, but not scar
reduction (19). It has been suggested that the relative
proportion of TGF-b isoforms, and not the absolute
concentration of any one isoform, determines the
wound repair outcome (12,14–16).
We have seen that TGF-b2 was significantly higher
in fetal skin dermal fibroblasts than in foreskin tissue
fibroblasts, but nomajor differences withTGF-b1 and
TGF-b3. When looking at expression of the three
isoforms in five different fetal skin cell lines, we have
observed that TGF-b1 gene expression is much
higher than that of TGF-b3. Importantly, variability
between fetal donors for the TGF-b isoforms was
very small, which is generally the opposite for that of
skin from young and old donors. Importance has
been given to the TGF-b3 isoform by a company in
England, Renovo Ltd., which used human recombi-
nant TGF-b3 (Juvista) in clinical trials showing 70%
response rate for scar reduction to date.
However, TGF-b1- and b2-neutralizing antibodies
do not entirely prevent scarring in the adult, and
other studies question the efficacy of TGF-b3 in
wound healing (19).
More recently, inhibition of TGFbRII-mediated
signaling was demonstrated with a gene therapy
approach in a rabbit hypertrophic scarring model
showing some reduction biologically. Lack of com-
plete reduction could either be due to the technical
difficulties suggested by the authors for low transduc-
tion efficiency, or it may suggest that factors other
than TGF-b may also be important in scarless repair.
As TGF-b’s particular importance in wound
healing is also due to their ability to modulate ECM
formation, two genes previously shown in wound
healing in fetal skin (LAMb1) and in hypertrophic
scar (DPT) were analyzed for differences between
fetal and foreskin tissue fibroblasts (20). DPT and
laminins have important roles in cell–matrix interac-
tions and matrix assembly, and DPT has been shown
to be decreased in hypertrophic scar and systemic
sclerosis skin fibroblasts (21). No significant differ-
ences were seen between fetal cells and foreskin cells
for these two selected ECM genes.
As wound healing is very complex, there are cer-
tainly many other molecules within the TGF-b super-
family which could have a role. For instance, BMP
family of genes and their receptors are among those in
the TGF-b superfamily genes, and have also been
strongly associatedwith cutaneouswoundhealing and
scarless wound healing in the fetus. Over-expression
of BMP-6 was shown to delay re-epitheliazation and
promote scar formation in a transgenic mouse model
(22).BMP-6 is important formaintaining skin homeo-
stasis and is 3.8 times higher expressed in fetal dermal
fibroblasts than in foreskin fibroblasts. GDF-10 or
BMP-3B seems to be more related to organogenesis
and was seen to be 11.8 times less expressed in fetal
skin cells.
More recent studies have shown evidence for the
importance of angiogenesis and nerve involvement
in wound repair (23,24). PTN, a cytokine-inducing
heparin-binding/differentiation, is certain to have a
major role in angiogenesis in wound healing. MDK
and PTN,which have 50% amino acid sequence iden-
tity and striking domain homology, are the two
members of the Ptn/Mdk developmental gene family
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FIG. 3. Expression of TGF-b isoform (TGF-b1, TGF-b2, and
TGF-b3) genes in cell lines that are 14 versus 16 weeks of
gestation. Male fetal skin cell lines (three at 14 weeks of gestation
[F1–3] and two at 16 weeks [F4 and 5]) were analyzed for
isoforms of TGF-b.
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(24). In the two nerve growth factor genes studied
here,MDK was about 36 times less expressed in fetal
skin than in foreskin cells, and PTN was 4.76 times
more expressed in foreskin tissue than fetal cells.
Interestingly, PTN has been recently shown to induce
functional neovasculature in vivo (24).As fetal tissue
heals with no inflammatory response, lower MDK
and PTN expression is perhaps preferable as it has an
important role in angiogenesis.
Overall, we have seen differences between fetal
and foreskin dermal fibroblasts in six of nine genes
involved in wound healing analyzed by real-time
RT–PCR. In a study using Northern analysis to look
at gene expression differences between fetal and
adult cells, detection was not possible for most
growth factors tested. For the TGF isoforms, only
TGF-b1 was detectable, and no differences were seen
between the two cell types similar to what we have
seen with fetal and foreskin fibroblasts. Indeed,
individual growth factors (TGF-b2, TGF-b3, IL-10,
PDGF) have been shown in the clinic to help in dif-
ferent aspects of overall wound healing, but it is a
very complex process (14,15). Most likely, many
factors taken together are necessary for complete
wound closure which could indeed be offered by a
cell-based therapy.
Biological products available for clinical use for
wound closure can be divided into either autologous
or allogenous, and the advantages and disadvantages
of these products are presented in Table 1. As the
“gold standard,” patient’s own skin (often from the
scalp for pediatric burns or thighs for ulcers, wounds,
and burns) is commonly used as a source of graft
material, but this unfortunately creates additional
wound sites. At least for burns, skin from related
donors such as family members having similar
genetic markers has also been used. However, doing
so requires the coadministration of powerful immu-
nosuppressant drugs to lessen the patient’s immune
system so that the graft would not be rejected, but
crippling the patient’s immune system posing addi-
tional, serious problems for the patient. Interestingly,
fetal skin cells are preimmunocompetent and associ-
ated with a reduced capacity to evoke an immuno-
logical response in the recipient of such cells (25).
Described earlier, there are various techniques for
cutaneous tissue engineering and skin replacement
using different cell sources and delivery systems with
varying advantages and disadvantages. For the most
part, autologous grafting requires an initial biopsy
from the patient, and the cell production processing is
cumbersome and long before delivery even with the
new methods of “sprayed on skin.” Allograft prepa-
rations to date require multiple tissue donations, and
none of these procedures has been shown to provide
full wound closure (Tables 1 and 2) (1,26,27).
Importantly, allografts developed from fetal der-
mal fibroblast banks associated with a biodegradable
collagen matrix show that a biological skin substitute
is capable of providing a very high quality of skin
repair/replacement in a short period of time with no
additional grafting technique necessary (48 h prepa-
ration necessary to deliver to patient). It had been
shown in other studies that when grafts were pre-
pared with a majority of dermal fibroblasts in propor-
tion to keratinocytes, the stimulation of healing was
much greater. The need for dermal components to
avoid secondary scar contraction and to assist in a
good aesthetical and mechanical result of tissue
repair has been well accepted (28). Using only fetal
skin fibroblasts, instead of bilayered skin constructs, is
therefore a unique and simplified method for provid-
ing total wound closure, and thus increases the con-
sistency and safety for the processing of the fetal skin
constructs, especially because these cells grow rapidly
with only minimal growth requirements, and inte-
grate uniformly and rapidly into a collagen matrix
delivery system providing an “off-the-shelf” wound
healing construct.
CONCLUSIONS
Overall, even under the most optimal conditions,
adult cutaneous repair necessitates autografting
and/or two-step surgical procedures, and ultimately
results with scar. Thus, fetal skin represents the ideal
paradigm of all tissue repair due to its inherent ability
to repair through regeneration rather than scar. Dif-
ferences of expression in wound healing gene fami-
lies between fetal cells and other cell types used in
biological preparations could be responsible for
more efficient repair processes. The results herein
lead to the realization that many factors taken
together are necessary for complete wound closure
which could indeed be offered by a cell-based
therapy instead of the delivery of one isolated growth
factor. Optimization of the choice of allogeneic cell
type and their associated isolation and proliferation
consistency along with the specific delivery system
will be essential for assuring increasing patients ben-
efiting from tissue engineering in the future.
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